Skip to main content
. 2011 Aug 31;6(8):e24334. doi: 10.1371/journal.pone.0024334

Figure 3. Activity of 832-4, 838 and GCV against a GCV-resistant CMV strain.

Figure 3

A plaque reduction assay was used to quantify the inhibition of the GCV-resistant CMV. CMV-infected HFF were treated with 832-4, 838 and GCV at the indicated concentrations. Plaques were counted 21 days post infection.